BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Core Viewpoint - BioMarin Pharmaceutical is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion [1] Company Summary - The acquisition will enhance BioMarin's portfolio and expand its capabilities in the biotechnology sector [1] - The deal signifies BioMarin's strategic move to strengthen its position in the market through consolidation [1] Financial Summary - The total value of the acquisition is around $4.8 billion, indicating a significant investment by BioMarin [1]